Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019

Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloch, Evan M, Focosi, Daniele, Shoham, Shmuel, Senefeld, Jonathon, Tobian, Aaron A R, Baden, Lindsey R, Tiberghien, Pierre, Sullivan, David J, Cohn, Claudia, Dioverti, Veronica, Henderson, Jeffrey P, So-Osman, Cynthia, Juskewitch, Justin E, Razonable, Raymund R, Franchini, Massimo, Goel, Ruchika, Grossman, Brenda J, Casadevall, Arturo, Joyner, Michael J, Avery, Robin K, Pirofski, Liise-anne, Gebo, Kelly A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Viewpoints Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249987/
https://www.ncbi.nlm.nih.gov/pubmed/36740590
http://dx.doi.org/10.1093/cid/ciad066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249987/
https://www.ncbi.nlm.nih.gov/pubmed/36740590
http://dx.doi.org/10.1093/cid/ciad066

Ejemplares similares